Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis.

IF 4.2 2区 医学 Q1 ANESTHESIOLOGY European Journal of Anaesthesiology Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI:10.1097/EJA.0000000000002042
Eduardo Maia Pereira, Vitor Ryuiti Moraes, Mariana Gaya da Costa, Tatiana Souza do Nascimento, Eric Slawka, Carlos Galhardo Júnior, Michel Mrf Struys
{"title":"Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis.","authors":"Eduardo Maia Pereira, Vitor Ryuiti Moraes, Mariana Gaya da Costa, Tatiana Souza do Nascimento, Eric Slawka, Carlos Galhardo Júnior, Michel Mrf Struys","doi":"10.1097/EJA.0000000000002042","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elderly patients comprise an increasing proportion of patients undergoing surgery, and they require special attention due to age-related physiological changes. Propofol is the traditional agent for anaesthesia, and recently, remimazolam, a novel ultra-short-acting benzodiazepine, has emerged as an alternative to propofol in general anaesthesia.</p><p><strong>Objectives: </strong>We aim to compare remimazolam vs . propofol for general anaesthesia in elderly patients regarding hypotension, induction characteristics, haemodynamics and recovery outcomes.</p><p><strong>Design: </strong>Meta-analysis with sensitivity and trial sequential analyses (TSA) to assess inconsistencies. Risk ratios and mean differences with 95% confidence intervals (95% CIs) were computed using a random effects model. Subgroups and meta-regression according to anaesthesia methods were also performed.</p><p><strong>Data sources: </strong>We systematically searched MEDLINE, Embase and Cochrane for randomised controlled trials (RCTs) up to January 1, 2024.</p><p><strong>Eligibility criteria: </strong>Patients at least 60 years old, comparing remimazolam vs . propofol for general anaesthesia.</p><p><strong>Results: </strong>Eleven RCTs (947 patients) were included. Compared with propofol, remimazolam was associated with lower postinduction and intra-operative hypotension (RR 0.41, 95% CI 0.27 to 0.62, P  < 0.001) and incidence of bradycardia (risk ratio 0.58, 95% CI 0.34 to 0.98, P  = 0.04), with a higher heart rate ( P  = 0.01). The incidence of injection pain was lower ( P  < 0.001), but remimazolam was associated with a longer time to loss of consciousness ( P  < 0.001) and a higher bispectral index at loss of consciousness ( P  = 0.04). No differences were found for mean arterial pressure, emergence time, extubation time and incidence of emergence agitation. The TSA was consistent and achieved the required information size for hypotension.</p><p><strong>Conclusions: </strong>Remimazolam significantly reduced the risk of hypotension, bradycardia and injection pain, despite an increase in the time to loss of consciousness. Remimazolam appears to be an effective and well tolerated alternative to propofol in elderly patients undergoing general anaesthesia.</p>","PeriodicalId":11920,"journal":{"name":"European Journal of Anaesthesiology","volume":" ","pages":"738-748"},"PeriodicalIF":4.2000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377052/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Anaesthesiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/EJA.0000000000002042","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Elderly patients comprise an increasing proportion of patients undergoing surgery, and they require special attention due to age-related physiological changes. Propofol is the traditional agent for anaesthesia, and recently, remimazolam, a novel ultra-short-acting benzodiazepine, has emerged as an alternative to propofol in general anaesthesia.

Objectives: We aim to compare remimazolam vs . propofol for general anaesthesia in elderly patients regarding hypotension, induction characteristics, haemodynamics and recovery outcomes.

Design: Meta-analysis with sensitivity and trial sequential analyses (TSA) to assess inconsistencies. Risk ratios and mean differences with 95% confidence intervals (95% CIs) were computed using a random effects model. Subgroups and meta-regression according to anaesthesia methods were also performed.

Data sources: We systematically searched MEDLINE, Embase and Cochrane for randomised controlled trials (RCTs) up to January 1, 2024.

Eligibility criteria: Patients at least 60 years old, comparing remimazolam vs . propofol for general anaesthesia.

Results: Eleven RCTs (947 patients) were included. Compared with propofol, remimazolam was associated with lower postinduction and intra-operative hypotension (RR 0.41, 95% CI 0.27 to 0.62, P  < 0.001) and incidence of bradycardia (risk ratio 0.58, 95% CI 0.34 to 0.98, P  = 0.04), with a higher heart rate ( P  = 0.01). The incidence of injection pain was lower ( P  < 0.001), but remimazolam was associated with a longer time to loss of consciousness ( P  < 0.001) and a higher bispectral index at loss of consciousness ( P  = 0.04). No differences were found for mean arterial pressure, emergence time, extubation time and incidence of emergence agitation. The TSA was consistent and achieved the required information size for hypotension.

Conclusions: Remimazolam significantly reduced the risk of hypotension, bradycardia and injection pain, despite an increase in the time to loss of consciousness. Remimazolam appears to be an effective and well tolerated alternative to propofol in elderly patients undergoing general anaesthesia.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对老年患者进行全身麻醉时,雷马唑仑与异丙酚的对比:一项荟萃分析与试验序列分析。
背景:老年患者在接受手术的患者中所占的比例越来越大,由于与年龄有关的生理变化,他们需要特别关注。丙泊酚是传统的麻醉药,最近,一种新型超短效苯二氮卓类药物瑞马唑仑出现,成为丙泊酚在全身麻醉中的替代药物:我们旨在比较雷马唑仑与异丙酚在老年患者全身麻醉中的低血压、诱导特征、血流动力学和恢复结果:设计:带敏感性和试验序列分析(TSA)的 Meta 分析,以评估不一致性。采用随机效应模型计算风险比和平均差异及95%置信区间(95% CI)。还根据麻醉方法进行了分组和元回归:我们系统检索了 MEDLINE、Embase 和 Cochrane 中截至 2024 年 1 月 1 日的随机对照试验 (RCT):至少60岁的患者,比较瑞马唑仑与异丙酚用于全身麻醉的效果:结果:共纳入 11 项 RCT(947 名患者)。与异丙酚相比,瑞马唑仑可降低诱导后和术中低血压(RR 0.41,95% CI 0.27 至 0.62,P 结论:瑞马唑仑可显著降低术中低血压的发生率:尽管意识丧失时间延长,但瑞马唑仑可明显降低低血压、心动过缓和注射疼痛的风险。对于接受全身麻醉的老年患者来说,雷马唑仑似乎是一种有效且耐受性良好的异丙酚替代药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
11.10%
发文量
351
审稿时长
6-12 weeks
期刊介绍: The European Journal of Anaesthesiology (EJA) publishes original work of high scientific quality in the field of anaesthesiology, pain, emergency medicine and intensive care. Preference is given to experimental work or clinical observation in man, and to laboratory work of clinical relevance. The journal also publishes commissioned reviews by an authority, editorials, invited commentaries, special articles, pro and con debates, and short reports (correspondences, case reports, short reports of clinical studies).
期刊最新文献
A big little problem - postoperative nausea and vomiting incidences are too low! Is it time to add the letter E to the airway management guidelines? Is permissive hypercapnia really pneumoprotective? Reply to: importance of accounting for repeated measure designs when evaluating treatment effects at multiple postoperative days. Rethinking the utility of comparative studies between direct and video laryngoscopy in neonates and infants.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1